Immunic (IMUX) Total Non-Current Liabilities (2013 - 2026)
Immunic (IMUX) posted Total Non-Current Liabilities of $146000.0 for Q1 2026, up 36.45% sequentially from $107000.0 in Q4 2025, and down 30.48% YoY from $210000.0 in Q1 2025.
Immunic (IMUX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Immunic has reported Total Non-Current Liabilities for 14 years, with the latest figure at $146000.0 in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 30.48% year-over-year to $146000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146000.0 (down 30.48% YoY) and the FY2025 annual result came in at $107000.0, down 59.47% from the prior year.
- Total Non-Current Liabilities climbed to $146000.0 in Q1 2026 per IMUX's latest filing, from $107000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.4 million in Q1 2023 and troughed at $107000.0 in Q4 2025.
- A 5-year average of $504235.3 and a median of $407000.0 in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities surged 198.28% in 2023, then plunged 80.15% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $992000.0 in 2022, then plunged by 35.58% to $639000.0 in 2023, then sank by 58.69% to $264000.0 in 2024, then plunged by 59.47% to $107000.0 in 2025, then surged by 36.45% to $146000.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $146000.0, $107000.0, and $126000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Immunic | 682.77 Mn | 682.77 Mn | - | 328,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 328,000.00 |
| Mar 31, 2026 | 146,000.00 |
| Dec 31, 2025 | 107,000.00 |
| Sep 30, 2025 | 126,000.00 |
| Jun 30, 2025 | 205,000.00 |
| Mar 31, 2025 | 210,000.00 |
| Dec 31, 2024 | 264,000.00 |
| Sep 30, 2024 | 186,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 433,000.00 |
| Dec 31, 2023 | 639,000.00 |
| Sep 30, 2023 | 789,000.00 |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.35 Mn |
| Dec 31, 2022 | 992,000.00 |
| Sep 30, 2022 | 759,000.00 |
| Jun 30, 2022 | 407,000.00 |
| Mar 31, 2022 | 502,000.00 |
| Dec 31, 2021 | 584,000.00 |
| Sep 30, 2021 | 701,000.00 |